Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

394
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
394
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

154
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
154
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

248
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
248
Factors Influencing Drug Absorption: Drug Dissolution01:27

Factors Influencing Drug Absorption: Drug Dissolution

1.1K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.1K
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

462
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
462
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

225
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
225

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Efficacy, IHS Guideline Adherence, and Methodological Quality of Noninvasive Neuromodulation Clinical Trials in Migraine and Cluster Headache: A Systematic Review.

European journal of neurology·2026
Same author

Correction: What's a migraine day? Towards a consensus definition for clinical care and research - a Delphi panel-based study.

The journal of headache and pain·2026
Same author

Efficacy of a multidisciplinary 5-day headache day-clinic program: A prospective quasi-experimental pre-post study in primary headache disorders.

Headache·2026
Same author

What's a migraine day? Towards a consensus definition for clinical care and research - a Delphi panel-based study.

The journal of headache and pain·2026
Same author

Sex-specific management of migraine a systematic review and consensus statement from the European Headache Federation (EHF).

The journal of headache and pain·2026
Same author

The role of self-efficacy and control beliefs in response to a multimodal headache intervention: results from a prospective observational study with a waiting-list comparator.

Scientific reports·2026

Video Experimental Relacionado

Updated: Jan 24, 2026

Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.4K

Fármacos para la profilaxis de la migraña

Hans Christoph Diener, Julia Grans, Uwe Reuter

    Deutsches Arzteblatt international
    |January 23, 2026
    PubMed
    Resumen

    Los nuevos fármacos profilácticos para la migraña, incluidos los anticuerpos monoclonales y los gepantes, son eficaces y bien tolerados. Ofrecen una opción valiosa para pacientes que no responden a los tratamientos tradicionales.

    Palabras clave:
    migrañaprofilaxisanticuerpos monoclonalesgepantestratamientoneurologíafarmacología

    Más Videos Relacionados

    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
    10:39

    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

    Published on: June 2, 2014

    18.7K
    Modeling Neural Immune Signaling of Episodic and Chronic Migraine Using Spreading Depression In Vitro
    16:13

    Modeling Neural Immune Signaling of Episodic and Chronic Migraine Using Spreading Depression In Vitro

    Published on: June 13, 2011

    20.4K

    Videos de Experimentos Relacionados

    Last Updated: Jan 24, 2026

    Investigating Migraine-Like Behavior Using Light Aversion in Mice
    05:23

    Investigating Migraine-Like Behavior Using Light Aversion in Mice

    Published on: August 11, 2021

    4.4K
    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
    10:39

    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

    Published on: June 2, 2014

    18.7K
    Modeling Neural Immune Signaling of Episodic and Chronic Migraine Using Spreading Depression In Vitro
    16:13

    Modeling Neural Immune Signaling of Episodic and Chronic Migraine Using Spreading Depression In Vitro

    Published on: June 13, 2011

    20.4K

    Área de la Ciencia:

    • Neurología
    • Farmacología

    Sus antecedentes:

    • Los ataques de migraña frecuentes o graves requieren estrategias de tratamiento profiláctico.
    • Los medicamentos profilácticos orales tradicionales tienen perfiles de eficacia y tolerabilidad variables.

    Objetivo del estudio:

    • Revisar las directrices de la Sociedad Internacional de Cefaleas para la profilaxis de la migraña.
    • Evaluar la eficacia y tolerabilidad de los agentes profilácticos más nuevos para la migraña, incluidos los anticuerpos monoclonales y los gepantes.

    Principales métodos:

    • Revisión narrativa de la literatura y las directrices existentes.
    • Inclusión de metaanálisis sobre anticuerpos monoclonales y gepantes.
    • Resumen de la evidencia para fármacos profilácticos orales, anticuerpos monoclonales y gepantes.

    Principales resultados:

    • Los fármacos profilácticos orales mostraron reducciones modestas en los días de migraña en comparación con el placebo.
    • Los anticuerpos monoclonales dirigidos contra el péptido relacionado con el gen de la calcitonina (CGRP) o su receptor demostraron una eficacia significativa tanto en la migraña episódica como en la crónica.
    • Los gepantes (antagonistas del receptor CGRP) y la toxina botulínica A (onabotulinumtoxinA) son eficaces y bien tolerados, especialmente para pacientes con fracasos de tratamiento previos o migraña crónica con uso excesivo de medicación.

    Conclusiones:

    • Los nuevos medicamentos profilácticos para la migraña son eficaces y bien tolerados.
    • Estos agentes más nuevos proporcionan opciones terapéuticas cruciales para los pacientes que no responden o no toleran los tratamientos orales tradicionales o la toxina botulínica A.